Harvard Bioscience

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. It operates under the geographical segments: United States, Germany, United Kingdom, and Rest of the world. It sells its products through catalog, Website, distributors, and direct sales force. The company was founded by Dr. William T. Porter in 1901 and is headquartered in Holliston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Harvard Bioscience reports strong Q4 earnings, eyes China growth

Harvard Bioscience delivered solid financial performance in Q4 2022 with revenue growth and strong margins.
The company faces challenges in supply chain issues and debt reduction but is focused on growth opportunities.
Strategic plans for new product development and improving gross margins are key priorities for future success.

Harvard Bioscience reports strong Q1 earnings, eyes growth opportunities

Harvard Bioscience delivered solid Q1 2023 results with revenue growth, improved margins, and enhanced profitability. While facing challenges in sales organization and market shifts, the company is strategically positioned to capitalize on opportunities for growth through new product offerings and operational efficiencies.

Harvard Bioscience reports mixed Q2 results, eyes growth opportunities

Harvard Bioscience's Q2 2023 performance showed slight revenue decline but notable improvements in margins and profitability.
The company's strengths include new product launches, positive financial metrics, and a promising revenue guidance for 2023.
Challenges include managing discontinued products impact, sales force effectiveness, and profitability.
Opportunities exist in leveraging new products, addressing challenges, and optimizing financial performance drivers.

Harvard Bioscience reports improved margins and profitability in Q3

Harvard Bioscience (HBIO) showed mixed performance in Q3 2023 with revenue decline but improved margins and profitability. The company aims to sustain growth through new product launches and service expansion while managing debt effectively.

Harvard Bioscience reports Q4 results, eyes growth through new products

Harvard Bioscience reported mixed Q4 2023 results with revenue decline in some regions.
The company aims for long-term growth through new products and market expansion.
Challenges include revenue decline in certain regions and maintaining/improving margins.
Opportunities lie in new product launches, partnerships, and market expansion strategies.

Harvard Bioscience faces Q1 revenue dip, eyes second-half turnaround

Harvard Bioscience navigated a tough Q1 marked by revenue declines in key regions and operational challenges. However, the company's focus on new product launches and efficiency in maintaining a strong gross margin are positive indicators. Looking ahead, Harvard Bioscience anticipates a turnaround in the second half of the year with improved margins and overall performance.

Harvard Bioscience reports Q3 revenue decline, eyes growth opportunities

Harvard Bioscience faced revenue decline in Q3 due to China and Asia Pacific weakness but expects stabilization and growth.
Operational improvements and cost reductions are enhancing efficiency and profitability.
New product launches and focus on high-growth areas position the company for incremental growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HOLLISTON, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (“Harvard Bioscience”) today announced the refinancing of its debt with the closing of a new $65 million credit facility (the “Refinancing”). Proceeds from the new facility will be used to retire existing debt and pay related fees and expenses. The Refinancing significantly reduces borrowing costs while increasing operating flexibility through less restrictive financial covenants and access to higher levels of revolver borrowings.   

Harvard Bioscience Announces New Credit Facility

HOLLISTON, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO), today announced that Jim Green, Chairman, President and CEO, and Michael Rossi, CFO will participate in The Benchmark Company's 9th Annual Discovery One-on-One Conference. The virtual event will take place on Wednesday, November 18, 2020 with virtual investor meetings held throughout the day. 

Harvard Bioscience to attend Benchmark's 9th Annual Discovery One-on-One Conference

Harvard Bioscience, Inc. (HBIO) CEO Jim Green on Q3 2020 Results - Earnings Call Transcript

HOLLISTON, MA., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for third quarter ended September 30, 2020 before the market opens on November 5, 2020, and will hold a conference call to discuss the results on November 5, 2020 at 8:00 a.m. Eastern Time.

Harvard Bioscience Schedules Third Quarter 2020 Earnings Conference Call for November 5, 2020 at 8:00 AM ET

HOLLISTON, Mass., Sept.  16, 2020  (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, President and CEO, will present at the Singular Research Compelling Values 2020 Webinar on September 17, 2020 at 2:15  p.m. ET.

Harvard Bioscience to Present at Singular Research Compelling Values Webinar

Harvard Bioscience's (HBIO) CEO Jim Green on Q2 2020 Results - Earnings Call Transcript

HOLLISTON, Mass., July  20, 2020  (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for second quarter ended June 30, 2020 before the market opens on August 5, 2020, and will hold a conference call to discuss the results on August 5, 2020 at 8:00 a.m. Eastern Time.

Harvard Bioscience Schedules Second Quarter 2020 Earnings Conference Call for August 5, 2020 at 8:00 AM ET

Provides Update on Performance Against Previously Announced Strategic Plan Provides Update on Performance Against Previously Announced Strategic Plan

Harvard Bioscience, Inc. Issues Letter to Shareholders

Harvard Bioscience, Inc.'s (HBIO) CEO Jim Green on Q1 2020 Results - Earnings Call Transcript

Mettler-Toledo

PerkinElmer

Waters

Drab Near-Term Prospects for Scientific Instruments Industry

Harvard Bioscience (HBIO) delivered earnings and revenue surprises of -125.00% and -15.10%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Harvard Bioscience (HBIO) Reports Q1 Loss, Lags Revenue Estimates

BuildABear

Green Brick Partners

Kinross Gold

Methode Electronics

The S&P 500 posted solid gains of 20.8%, 18% and 10.4% in the 12-month period after the first occurrence of SARS, MERS and Ebola back in 2003, 2013 and 2014, respectively.

5 of the Best Stocks to Buy for a Post-Pandemic Rally

Engine Capital Withdraws Director Nomination Notice For 2020 Annual Meeting of Stockholders

Harvard Bioscience Announces Appointment of Susan Steele to Board of Directors

Company will continue to manufacture and ship innovative products for global development and research throughout crisis Company will continue to manufacture and ship innovative products for global development and research throughout crisis

Harvard Bioscience Introduces Next Generation Inhalation System to Aid in the Fight Against COVID-19

Harvard Bioscience, Inc.'s (HBIO) CEO Jim Green on Q4 2019 Results - Earnings Call Transcript

Scientific Instruments Industry Outlook: Prospects Look Good

Harvard Bioscience has been struggling lately, but the selling pressure may be coming to an end soon.

Harvard Bioscience Sees Hammer Chart Pattern: Time to Buy?

Harvard Bioscience (HBIO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Why Harvard Bioscience (HBIO) Might be Well Poised for a Surge

Harvard Bioscience, Inc. (HBIO) CEO Jim Green on Q3 2019 Results - Earnings Call Transcript

Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 0.00% and -3.80%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Harvard Bioscience (HBIO) Matches Q3 Earnings Estimates

HOLLISTON, Mass., Nov.  01, 2019  (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that in connection with Yash Singh being named Executive Vice President, Cellular & Molecular Technologies on October 31, 2019, the Compensation Committee of the Board of Directors approved the grant of equity awards to Mr. Singh as equity inducement awards outside of the Company's Third Amended and Restated 2000 Stock Option and Incentive Plan and material to the employee's acceptance of employment with the Company. The equity awards were granted on October 31, 2019 and approved in accordance with Nasdaq Listing Rule 5635(c)(4).  Such equity awards include an option to acquire 86,614 shares of common stock of the Company as well as market condition deferred stock award of restricted stock units with a target share amount of 39,286, each with vesting subject to Mr. Singh’s continued employment with Harvard Bioscience on such vesting dates.  The stock option has an exercise price of $2.80, being the closing price of Harvard Bioscience’s common stock on the grant date, and vests in four equal annual installments commencing one year from the grant date and continuing on the next three anniversaries of such date thereafter. The market condition award has a final award amount determined based on the achievement of a relative total shareholder return, of the Company’s common stock from the grant date to the earlier of (a) October 31, 2020, being the anniversary of the grant date, or (b) upon a change of control, and measured relative to the NASDAQ Biotechnology index during such period.  The maximum number of market condition restricted stock units that may be earned is 150% of the target and would be achieved if the relative total shareholder return is at or above the 75th percentile of companies in the index and if the relative total shareholder return is below the 20th percentile, the market condition award will not vest and the award will be forfeited.  The final achieved market condition award amount vests in equal installments on each of October 31, 2020, 2021, and 2022.

Harvard Bioscience Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HOLLISTON, Mass., Oct.  31, 2019  (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that Yash Singh has been named Executive Vice President, Cellular & Molecular Technologies, reporting to Chairman, President and CEO, Jim Green. 

Harvard Bioscience Announces Executive Appointment

Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Harvard Bioscience (HBIO) Q3 Earnings Preview: What's in the Cards?

HOLLISTON, Mass., Oct.  21, 2019  (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that Ken Olson has been named Vice President and General Manager, Pre-Clinical Systems (DSI), reporting to Chairman, President and CEO, Jim Green.

News for Harvard Bioscience Stock (HBIO)